| Income Statement | 2025-10-31 | |||
|---|---|---|---|---|
| General and administrative | 303,190 | |||
| Loss from operations | -303,190 | |||
| Loss from change in fair value of oragenics, inc. common stock | 0 | |||
| Interest expense | 95,336 | |||
| Financing costs | 507,368 | |||
| Change in fair value of derivative liability | 422,419 | |||
| Other income, net | 28 | |||
| Net loss and comprehensive loss | -483,447 | |||
| Basic net loss per share | 0 | |||
| Diluted net loss per share | 0 | |||
| Shares used for basic net loss per share | 106,036,632 | |||
| Shares used for diluted net loss per share | 106,036,632 | |||
Odyssey Health, Inc. (ODYY)
Odyssey Health, Inc. (ODYY)